EXEL Projected Dividend Yield
Exelixis Inc ( NASDAQ : EXEL )Exelixis is an oncology company that engages in creating medicines and combination regimens for cancer care. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved both alone and in combination with Bristol-Myers Squibb Company's OPDIVO® (nivolumab) for renal cell carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan. 20 YEAR PERFORMANCE RESULTS |
EXEL Dividend History Detail EXEL Dividend News EXEL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |